Alnylam Pharmaceuticals reported mixed Q3 earnings for the quarter ending September 30, 2024, with net product revenues rising to $420.1 million, up from $313.2 million the previous year. However, the company faced a net loss of $111.6 million, a decline from a net income of $147.8 million, primarily due to increased research and development expenses. Strategic collaborations with companies like Roche and Regeneron are expected to bolster future growth as Alnylam focuses on expanding its RNAi therapeutics pipeline.
The global diabetic retinopathy devices market, valued at USD 12.47 billion in 2022, is projected to grow at a robust CAGR of around 30% through 2030, driven by rising diabetes cases and an aging population. Non-proliferative diabetic retinopathy is expected to dominate, while North America will lead regionally, with significant contributions from the APAC region due to its large diabetic population. Key players include F. Hoffmann-La Roche, Novartis, and Regeneron, focusing on innovative treatments and technologies.
The drug and biotech sector is experiencing a strong earnings season, highlighted by Johnson & Johnson's recent performance, which exceeded estimates and led to an upward revision of revenue expectations. Five large drug companies—Novo Nordisk, Novartis, Pfizer, Regeneron Pharmaceuticals, and Biogen—are anticipated to outperform in their upcoming quarterly results, with Novo Nordisk showing a positive Earnings ESP of +1.02% and a Zacks Rank #3. Overall, the Medical sector is projected to see a 6.4% rise in fourth-quarter earnings and an 8.5% increase in revenues.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
